The short version.
MOTS-c is one of a small group of mitochondrial-derived peptides — peptides encoded by mitochondrial DNA rather than nuclear DNA. It was characterized by the Cohen lab at USC starting around 2015. Mechanistically, MOTS-c acts on AMPK and influences glucose handling, insulin sensitivity, and exercise capacity in animal models.
The endurance interest is grounded: in mice, MOTS-c administration improves treadmill performance, especially in older animals. The case for human use as an endurance tool is being built — early human data exists, but full RCTs in athletes don't.
What the literature actually says.
The strongest signals come from preclinical work: MOTS-c-treated mice run further, recover better, and show improved insulin sensitivity. The proposed mechanism — AMPK activation, increased glucose uptake, mitochondrial efficiency — is consistent with what an endurance peptide would mechanistically need to do.
Human data is limited. There are pharmacokinetic studies and small early-phase trials in metabolic populations, but you won't find a placebo-controlled VO2max trial in trained athletes. Anecdotally, athletes using MOTS-c report subjective improvements in recovery and capacity; that's information, not evidence.
The honest framing: MOTS-c is one of the more biologically interesting peptides in the metabolic/endurance space, with a real mechanistic story and credible animal data. The human endurance case is plausible-but-unproven, and athletes should be clear-eyed about that gap.
The mouse data is striking. The human endurance case is plausible-but-unproven. Athletes should know that gap exists.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Given the early human data, what's the realistic expectation for a trained athlete?
- Where does WADA / sport-specific testing currently stand on mitochondrial peptides?
- What's a reasonable trial period before reassessing?
- Are there metabolic labs (glucose, insulin sensitivity) worth checking before and during?
- Does it make more sense as a periodized tool around training blocks?
Sources